HCP1105

DRUG2 trials

Sponsors

Hanmi Pharmaceutical Company Limited

Conditions

Hyperlipidemias

Phase 1

Pharmacokinetics and Safety of HCP1105 and Co-administration of HGP0918, HGP0816 in Healthy Male Volunteers

CompletedNCT02941796

Hanmi Pharmaceutical Company LimitedHyperlipidemias

Start: 2016-06-30End: 2016-10-31Updated: 2016-10-21

Phase 3

Evaluating the Efficacy and Safety of HCP1105 in Combined Hyperlipidemic Patients With High Risk for CHD

Hanmi Pharmaceutical Company LimitedHyperlipidemias

Start: 2014-10-31End: 2016-02-29Target: 270Updated: 2015-09-16